Folosim cookie-uri pentru a îmbunătăți experiența pe site. Pentru detalii, citește Politica de confidențialitate.

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

10.11.2026 15:00 | The Guardian World

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatmentThe gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by companies on weight loss, according to a report from the Netherlands-based non-profit group. Continue reading...

🔗 Citește articolul complet pe The Guardian World